India’s Central Drugs Standard Control Organization has approved the oral therapy nor-ursodeoxycholic acid (NorUDCA) for people with metabolic dysfunction-associated steatotic liver disease (MASLD), a form…
People with Alagille syndrome display different disease characteristics depending on whether the disease-causing mutation is located in the JAG1 gene or the NOTCH2 gene,…
The first participant has been dosed in a Phase 2 clinical trial testing Aligos Therapeutics’ oral treatment candidate ALG-000184 in people chronically infected with…
People with primary sclerosing cholangitis (PSC) have a six times higher risk of cancer affecting the large intestine or rectum, and that risk remained…
A new artificial intelligence (AI) algorithm can help identify babies with genetic forms of cholestasis, including progressive familial intrahepatic cholestasis (PFIC), using data from…
The proportion of cases of hepatocellular carcinoma (HCC) attributable to fatty liver disease is set to rise in the next 25 years, with obesity…
A new study has uncovered a key mechanism behind the liver scarring seen in biliary atresia (BA), a rare liver disease in infants. Two…
The first participant has been enrolled in ECLIPSE 3, a Phase 2b clinical trial testing Vir Biotechnology’s combination treatment of tobevibart and elebsiran against…
Adding vitamin D to ursodeoxycholic acid (UDCA) treatment is superior to UDCA alone at reducing symptoms, liver damage markers, and liver scarring in previously untreated…
Low levels of vitamin D by-products, or metabolites, in the blood are indicative of more severe liver damage in cholestasis, according to a small…
